FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A phase 2 trial of FPI-2265, Olaparib in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.
Overview
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06909825 by Fusion Pharmaceuticals Inc., with 85 participants planned, started 2025-02-26 and due to reach its primary completion in 2027-05. Interventions recorded: FPI-2265, Olaparib. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTargeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Shares Olaparib, AstraZeneca, Prostate cancer.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, AstraZeneca.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, AstraZeneca.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, AstraZeneca.
- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, AstraZeneca.